Silver Book Fact

Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.

Black, Dennis M. Desmond E. Thompson, Douglas C. Bauer, Kris Ensrud, Thomas Musliner, Marc C. Hochberg, Michael C. Nevitt, Shailaja Suryawanshi, and Steven R. Cummings; for the FIT Research Group. Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The fracture intervention trial. J Clin Endocrinol Metabo. 2000; 85(11): 4118-24. http://jcem.endojournals.org/cgi/content/full/85/11/4118

Reference

Title
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The fracture intervention trial
Publication
J Clin Endocrinol Metabo
Publication Date
2000
Authors
Black, Dennis M. Desmond E. Thompson, Douglas C. Bauer, Kris Ensrud, Thomas Musliner, Marc C. Hochberg, Michael C. Nevitt, Shailaja Suryawanshi, and Steven R. Cummings; for the FIT Research Group
Volume & Issue
Volume 85, Issue 11
Pages
4118-24
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A study that looked at a combination of calcium and Vitamin D found that hip fractures were reduced by around 43%.  
  • A systematic review of osteoporosis therapies found good evidence that many are effective in preventing fractures, but concluded that the data are insufficient to determine if any one therapy is…  
  • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.  
  • Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.  
  • Reducing secondary bone fractures can reduce medicare spending
    Reducing 5-20 percent of “secondary” bone fractures in 2015 could have reduced Medicare FFS spending by $310 million to $1.2 billion over a follow-up period that lasted up to 2 to…